Business
MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference
75% survival in patients with severe respiratory distress treated with agenT-797agenT-797 improved lung function, significantly reduced inflammation and
About this update from Mink Therapeutics, Inc.
[{"type":"text","content":"75% survival in patients with severe respiratory distress treated with agenT-797agenT-797 improved lung function, significantly reduced inflammation and secondary infectionsMiNK to advance agenT-797 in ARDS through externally financed programs NEW YORK, May 22, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced presentation of clinical data from its allo-iNKTs (agenT-797) in COVID-19 associated Acute Respiratory Distress Syndrome (CARDS) at the American Thoracic Society (ATS) International Conference in Washington D.C. “The encouraging activity, tolerability, and ease of administration seen with allogeneic iNKT cells in patients with CARDS suggests the important role that cellular based therapies could play in infectious, inflammatory diseases, and autoimmunity,” said Dr. Terese C. Hammond, Medical Director, Providence Saint John’s Health Center and Sound Physicians. “Addressing immune system dysfunction is essential to improving outcomes in critical illness. I believe these results illuminate how novel immune cell interventions can have an impactful role in treating in acute critical illness.” Twenty patients with moderate to severe CARDS, including 4 patients on venovenous extracorporeal membrane oxygenation (VV ECMO) therapy, were treated with a single dose of agenT-797. Clinical results showed pronounced survival benefit and manageable safety profile including: Patients on VV ECMO treated with agenT-797 had 75% 90-day survival compared to 30% survival with in-hospital controls.agenT-797 was dosed to 1 billion cells with a tolerable safety profile, without oxygenation failure or other significant adverse events, including cytokine release syndrome (CRS).agenT-797 induced significant anti-inflammatory profile changes and improved lung function (radiologic) within 24 hours after administration in a patient on VV ECMO support.In the overall study, agenT-797 showed reduction in secondary infections, including an over 80% reduction in pneumonia at dose cohort 3 (1 X 10^9 cells). Bacterial pneumonia in one patient on VV ECMO cleared 12 days post-infusion of agenT-797. The ...